Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GMED NYSE:HAE NYSE:PEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$84.84+0.3%$87.26$51.79▼$101.40$11.51B11.81 million shs1.81 million shsHAEHaemonetics$65.48+5.7%$58.23$47.31▼$87.32$2.81B0.53882,817 shs1.04 million shsPENPenumbra$328.46+0.2%$329.87$221.26▼$362.41$12.90B0.74435,224 shs508,515 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical+0.45%+10.88%-10.62%-6.34%+43.14%HAEHaemonetics+5.97%+16.22%+7.13%+6.92%-2.10%PENPenumbra+0.20%+1.93%-1.21%-3.22%+21.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$84.84+0.3%$87.26$51.79▼$101.40$11.51B11.81 million shs1.81 million shsHAEHaemonetics$65.48+5.7%$58.23$47.31▼$87.32$2.81B0.53882,817 shs1.04 million shsPENPenumbra$328.46+0.2%$329.87$221.26▼$362.41$12.90B0.74435,224 shs508,515 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical+0.45%+10.88%-10.62%-6.34%+43.14%HAEHaemonetics+5.97%+16.22%+7.13%+6.92%-2.10%PENPenumbra+0.20%+1.93%-1.21%-3.22%+21.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMEDGlobus Medical 2.81Moderate Buy$106.3625.37% UpsideHAEHaemonetics 2.73Moderate Buy$77.1117.76% UpsidePENPenumbra 2.18Hold$361.3310.01% UpsideCurrent Analyst Ratings BreakdownLatest PEN, HAE, and GMED Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026HAEHaemonetics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$72.00 ➝ $80.005/21/2026HAEHaemonetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/12/2026HAEHaemonetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/12/2026HAEHaemonetics Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$94.00 ➝ $89.005/8/2026HAEHaemonetics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$67.005/8/2026GMEDGlobus Medical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$104.00 ➝ $103.005/8/2026GMEDGlobus Medical Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$115.00 ➝ $120.005/8/2026GMEDGlobus Medical Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$114.00 ➝ $117.005/8/2026HAEHaemonetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$74.00 ➝ $62.005/7/2026PENPenumbra EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$335.005/7/2026PENPenumbra CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$374.00 ➝ $350.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMEDGlobus Medical$3.10B3.71$6.30 per share13.47$34.86 per share2.43HAEHaemonetics$1.33B2.23$8.01 per share8.17$17.52 per share3.74PENPenumbra$1.40B9.20$4.31 per share76.27$37.47 per share8.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMEDGlobus Medical$537.87M$4.3019.7316.801.7418.92%13.46%11.65%8/6/2026 (Estimated)HAEHaemonetics$97.31M$2.0232.4211.391.257.29%27.30%9.59%8/6/2026 (Estimated)PENPenumbra$177.69M$4.3475.6851.082.0111.76%10.87%8.45%8/4/2026 (Estimated)Latest PEN, HAE, and GMED EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GMEDGlobus Medical$0.92$1.12+$0.20$0.90$740.35 million$759.85 million5/7/2026Q4 2026HAEHaemonetics$1.28$1.29+$0.01-$0.44$336.83 million$346.35 million5/6/2026Q1 2026PENPenumbra$1.06$0.82-$0.24$0.82$370.47 million$374.76 million2/25/2026Q4 2025PENPenumbra$1.12-$0.37-$1.49-$0.52$367.18 million$385.39 million2/24/2026Q4 2025GMEDGlobus Medical$1.06$1.28+$0.22$1.03$803.29 million$826.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMEDGlobus MedicalN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/APENPenumbraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMEDGlobus MedicalN/A4.562.95HAEHaemonetics1.532.951.87PENPenumbra0.016.023.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMEDGlobus Medical95.16%HAEHaemonetics99.67%PENPenumbra88.88%Insider OwnershipCompanyInsider OwnershipGMEDGlobus Medical18.38%HAEHaemonetics1.84%PENPenumbra2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMEDGlobus Medical6,000135.75 million110.80 millionOptionableHAEHaemonetics3,02345.45 million45.62 millionOptionablePENPenumbra4,70039.33 million38.19 millionOptionablePEN, HAE, and GMED HeadlinesRecent News About These CompaniesNew York Life Investment Management LLC Takes $999,000 Position in Penumbra, Inc. $PENMay 20 at 4:40 AM | marketbeat.com3,550 Shares in Penumbra, Inc. $PEN Bought by Radnor Capital Management LLCMay 19, 2026 | marketbeat.com120,815 Shares in Penumbra, Inc. $PEN Purchased by Stephens Investment Management Group LLCMay 17, 2026 | marketbeat.comThrivent Financial for Lutherans Sells 72,330 Shares of Penumbra, Inc. $PENMay 16, 2026 | marketbeat.comPenumbra, Inc. (NYSE:PEN) Given Average Rating of "Hold" by BrokeragesMay 12, 2026 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from AnalystsMay 12, 2026 | marketbeat.comWall Street Zen Upgrades Penumbra (NYSE:PEN) to HoldMay 9, 2026 | marketbeat.comAssessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E MultipleMay 7, 2026 | finance.yahoo.comPenumbra (NYSE:PEN) Price Target Cut to $350.00 by Analysts at CitigroupMay 7, 2026 | marketbeat.comUBS Group AG Has $46.75 Million Stock Position in Penumbra, Inc. $PENMay 7, 2026 | marketbeat.comPenumbra: Q1 Earnings SnapshotMay 6, 2026 | chron.comPenumbra launches 36th volume with readings, art and jazz performanceMay 6, 2026 | csusignal.comCPenumbra (NYSE:PEN) Releases Quarterly Earnings Results, Misses Expectations By $0.21 EPSMay 6, 2026 | marketbeat.comPenumbra (PEN) Misses Q1 Earnings EstimatesMay 6, 2026 | zacks.comPenumbra, Inc. Reports First Quarter 2026 Financial ResultsMay 6, 2026 | prnewswire.comStrs Ohio Sells 9,498 Shares of Penumbra, Inc. $PENMay 6, 2026 | marketbeat.comALC vs. PEN: Which Stock Should Value Investors Buy Now?May 5, 2026 | zacks.comHorizon Investments LLC Acquires 10,595 Shares of Penumbra, Inc. $PENMay 4, 2026 | marketbeat.comHussman Strategic Advisors Inc. Sells 8,400 Shares of Penumbra, Inc. $PENMay 4, 2026 | marketbeat.comVanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PENMay 2, 2026 | marketbeat.comInside Boston Scientific's $15 billion offer for Alameda's largest employerMay 2, 2026 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAlphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand NowBy Leo Miller | May 11, 2026Microsoft Earnings Look Strong, But Investors Focus on RisksBy Chris Markoch | April 30, 2026How Williams Companies Is Cashing in on the AI Power BoomBy Chris Markoch | May 6, 2026Amazon’s Earnings Just Sent the Stock to New Highs—What’s Next?By Sam Quirke | April 30, 2026PEN, HAE, and GMED Company DescriptionsGlobus Medical NYSE:GMED$84.84 +0.23 (+0.27%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$84.90 +0.07 (+0.08%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Haemonetics NYSE:HAE$65.48 +3.54 (+5.72%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$65.47 -0.01 (-0.02%) As of 05/22/2026 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Penumbra NYSE:PEN$328.46 +0.57 (+0.17%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$328.68 +0.23 (+0.07%) As of 05/22/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
